BUY Caplin Point Laboratories — Shrikant Chouhan, 24 Sept 2026

byShrikant Chouhan, Kotak SecuritiesHorizon: 1–3 months24 Sept 2026via NDTV Profit

Entry₹2,974.4Inferred

Target₹3,300

Stop lossNot given

CMP₹2,867.412h ago

Active-3.60%+15.09%upside left 3 mo left

Follow Shrikant Chouhan for new calls(39% target hit, 18 closed calls)Get alerts Watch CAPLIPOINT for new buy/sell callsGet alerts See 104 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Sept, 4:18 am IST

4 supporting3 neutral1 opposing

Supports the BUY call (4)

Past month's volume 2.8× the prior month's average

Technicals · volume·24 Sept · today

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·24 Sept · today

Caplin Point's Unit Gets Colombia's INVIMA GMP Compliance Nod for Oncology Drugs

NewsGoogle News·5 Sept · 3w ago

Caplin Point Subsidiary Gets Colombian GMP Certification

NewsGoogle News·1 Sept · 3w ago

Neutral / worth noting (3)

Caplin Point Labs schedules AGM with ₹8 per share dividend payout

NewsGoogle News·16 Sept · 1w ago

Caplin Point Labs schedules AGM with ₹8 per share dividend payout

NewsGoogle News·8 Sept · 2w ago

Caplin Point Laboratories: AGM Details and ₹8 Dividend

NewsGoogle News·3 Sept · 3w ago

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·24 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Caplin Point Laboratories Limited — Shrikant Chouhan, Kotak Securities

AI Assessment